Cleo Diagnostics Ltd (ASX:COV)

Australia flag Australia · Delayed Price · Currency is AUD
0.525
+0.020 (3.96%)
Last updated: Mar 10, 2026, 11:21 AM AEST
16.67%
Market Cap 69.12M
Revenue (ttm) 2.56M
Net Income (ttm) -4.03M
Shares Out 136.86M
EPS (ttm) -0.03
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 9,605
Average Volume 280,545
Open 0.520
Previous Close 0.505
Day's Range 0.520 - 0.525
52-Week Range 0.310 - 0.900
Beta 0.32
RSI 39.74
Earnings Date Feb 27, 2026

About Cleo Diagnostics

Cleo Diagnostics Ltd, a biotechnology company, focuses on the development and commercializing of non-invasive blood tests to detect ovarian cancer in Australia. The company offers CleoDX pre-surgical triage tests which measures a combination of five biomarkers in serum to provide an accurate determination of malignancy risk prior to surgical referral. It also focuses on developing and testing intellectual property, testing the IP, and securing patents. Cleo Diagnostics Ltd was incorporated in 2021 and is based in Melbourne, Australia. [Read more]

Industry Medical Devices
Sector Healthcare
Founded 2021
Country Australia
Stock Exchange Australian Securities Exchange
Ticker Symbol COV
Full Company Profile

Financial Performance

In fiscal year 2025, Cleo Diagnostics's revenue was 845,172, an increase of 300.91% compared to the previous year's 210,812. Losses were -4.00 million, 6.38% more than in 2024.

Financial Statements

News

There is no news available yet.